A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
← catalyst calendarNCT07184086 · readout in 419 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
80estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-26 | actual | When the study began enrolling |
| Primary completion | 2027-10-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: CagriSema (Cagrilintide B + semaglutide I)
- Behavioral: Low Energy Diet
Primary outcome
what the primary-completion date above is the date OFChange in sleeping metabolic rate (SMR)
measured Baseline (Week 0) to Week 20
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed